CAMBRIDGE, MA and PARIS, France, – September 28, 2018, at 8.30am CET – Lysogene (FR0013233475 – LYS) (the “Company”), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, provided today an update on its communication agenda.
As announced on July 23, 2018, the Company is focusing its efforts on the conclusion of a strategic transaction, or potential partnership of one or several of its products. The Company remains reasonably positive on the opportunity to conclude such a transaction as several discussions with potential interested parties are ongoing.
In this context, Lysogene postpones the publication of its financial report for the first six months ended June 30, 2018, which will now be made available to the public before the end of October 2018, together with its cash position at the end of Q3 2018. The Company will also communicate on the progress of its discussions regarding a potential transaction before the end of October 2018.
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A pivotal clinical trial in MPS IIIA and a phase 1-2 clinical trial in GM1 Gangliosidosis are in preparation, while we are currently collaborating with a major partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.
|Julie Coulot / Emmanuel Huynh|
|+ 33 1 44 71 20 40|
Forward looking statement
This press release may contain certain forward-looking statements, notably on the ability of the Company to conclude a strategic transaction or a potential partnership for one or several of its product candidates. Although the Company believes that these forward-looking statements are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control and (iii) the financial capabilities of the Company. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely”, “reasonably”, “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, contingencies and uncertainties can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2017 registration document (Document de référence), registered with the French Autorité des Marchés Financiers on June 4, 2018, under number R. 18-047, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward- looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.